Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ifosfamide + carboplatin + etoposide
- Development stage
- Unknown
- Lead developer
- NuGen Medical Devices
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
The combination of ifosfamide, carboplatin, and etoposide—commonly referred to as the ICE regimen—is a multi-agent chemotherapy protocol primarily used for cytoreduction and stem cell mobilization in patients with relapsed or refractory lymphomas (notably non-Hodgkin lymphoma) and is also used in small-cell lung cancer and other malignancies. Ifosfamide is an alkylating agent that crosslinks DNA, leading to apoptosis; carboplatin is a platinum-based compound that forms DNA adducts causing cell death; etoposide inhibits topoisomerase II, resulting in DNA strand breaks. The regimen is highly myelosuppressive but effective for tumor reduction prior to autologous stem cell transplantation. It may be administered with supportive agents such as mesna (to prevent hemorrhagic cystitis from ifosfamide) and granulocyte colony-stimulating factor (G-CSF) for hematopoietic support[1][2][3][7][8].
- Brand names
- VepesidEtopophosParaplatinIfex
- Other names
- ICE regimenifosfamide/carboplatin/etoposide
02
Targets
TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on ifosfamide + carboplatin + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ifosfamide + carboplatin + etoposide.